文献速递前列腺增生与排尿功能障碍

前列腺动脉栓塞术治疗良性前列腺增生相关下尿路症状:FDA批准的前瞻性IDE研究结果

Prostate Artery Embolization for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Results From a Prospective FDA-Approved Investigational Device Exemption Study.
PubMed 文献 · Urology · 2018-07-20

这项前瞻性单中心开放标签FDA批准研究纳入45例男性,评估前列腺动脉栓塞术(PAE)治疗良性前列腺增生(BPH)相关下尿路症状(LUTS)的安全性和有效性。结果显示PAE后1、3、6、12个月IPSS、QoL和Qmax均显著改善,前列腺总体积和中央腺体体积分别中位缩小18%和27%,无严重不良事件。

要点

  • PAE可显著改善BPH相关LUTS,1年时IPSS和QoL仍持续改善。
  • PAE后6个月前列腺总体积和中央腺体中位分别缩小18%和27%。
  • 不良事件多为自限性,无严重不良事件或对性功能的不良影响。

核心结论

  • PAE对BPH相关LUTS安全有效,可显著改善症状并缩小前列腺体积。

研究设计与样本

  • 前瞻性、单中心、开放标签、FDA批准的研究,纳入45例男性,随访至12个月。

主要发现

  • 1个月时IPSS从23.6±6.1降至12.0±5.9(P<.0001),QoL从4.8±0.9降至2.6±1.6(P<.0001),Qmax从5.8±1.0升至12.4±6.8 mL/s(P<.0001)。
  • 3个月时IPSS为10.2±6.0(P<.0001),QoL为2.4±1.6(P<.0001),Qmax为15.3±12.3 mL/s(P<.0001)。
  • 6个月时IPSS为11.0±7.6(P<.0001),QoL为2.3±1.7(P<.0001)。
  • 1年时IPSS为12.4±8.4(P<.0001),QoL为2.6±1.6(P<.0001)。
  • 前列腺总体积中位缩小18%(CI:13-27,P=0.0001),中央腺体中位缩小27%(CI:20-36,P=0.0001)。

关键数值与推荐

  • 纳入标准:年龄≥45岁,前列腺体积>40g,IPSS>13,Qmax≤12 mL/s,排尿量≥125 mL。
  • 自限性不良事件包括排尿困难(n=13)、血尿(n=6)、血精(n=2)、尿频(n=3)和尿潴留(n=2)。
  • 无严重不良事件、非靶栓塞或对勃起功能/性健康的不良影响。

临床怎么用

  • PAE可作为BPH相关LUTS的治疗选择,尤其适合希望避免手术或关注性功能保留的患者。

局限性

  • 单中心、开放标签、样本量45例,随访至1年,缺乏对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the safety and efficacy of prostate artery embolization (PAE) for lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia (BPH). METHODS: A prospective, single-center, open-label FDA-approved study was conducted to evaluate the safety and efficacy of PAE for LUTS secondary to BPH. We enrolled men ≥ 45, prostate volume > 40 g, International prostate symptom score (IPSS) > 13, peak flow rate (Qmax) ≤ 12 mL/s, and voided volume ≥ 125 mL. Patients were evaluated with questionnaires (IPSS, quality-of-life [QoL], International index of erectile function, and male sexual health questionnaire for ejaculatory dysfunction) and clinical measures (postvoid residual volume and Qmax at baseline 1, 3, and 12 months) after PAE. Baseline and 6-month total prostate (TV) and central gland (CG) volumes were obtained. RESULTS: 45 patients (mean volume: 99 cc, range: 30-214 g) were treated over the course of the 3-year study. At 1 month, there were improvements in IPSS (23.6 ± 6.1 to 12.0 ± 5.9, P < .0001), QoL (4.8 ± 0.9 to 2.6 ± 1.6, P < .0001), Qmax (5.8 ± 1.0 to 12.4 ± 6.8,P < .0001). At 3 months, there were improvements in IPSS (10.2 ± 6.0, P < .0001), QoL (2.4 ± 1.6, P < .0001) and Qmax (15.3 ± 12.3, P < .0001). At 6 months, there were improvements in IPSS (11.0 ± 7.6, P < .0001) and QoL (2.3 ± 1.7, P < .0001). At 1 year, there were improvements in IPSS (12.4 ± 8.4,P < .0001) and QoL (2.6 ± 1.6, P < .0001). There were reductions in postvoid volume residues: baseline 157 ± 45, 1 month 123 ± 47, P = .057, 3 months 127 ± 114, P = .34, 6 months 112±116, P = .002 and 1 year 109±116 P = .025. Median decreases in TV and CG were 18% (CI: 13-27) (P = 0.0001) and 27% (CI: 20-36)(P = 0.0001), respectively. Self-limited adverse events included dysuria (n = 13), hematuria (n = 6), hematospermia (n = 2), urinary frequency (n = 3) and retention (n = 2). No severe adverse events, nontarget embolization, or adverse effects on erectile function or sexual health. CONCLUSION: This prospective clinical trial demonstrates that PAE is safe and efficacious for BPH, with significant improvement in LUTS and reduction in TV and CG volumes.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Salem R, Hairston J, Hohlastos E, et al. Prostate Artery Embolization for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Results From a Prospective FDA-Approved Investigational Device Exemption Study. Urology. 2018. PMID: 30036614. doi:10.1016/j.urology.2018.07.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。